

January 19, 2012



# Resmed

## ResMed Announces Change to Outside US Dial-in Number for Conference Call and Webcast to Discuss Second Quarter 2012 Results

SAN DIEGO, Jan. 19, 2012 /PRNewswire/ -- RESMED INC. (NYSE: RMD), announced today that on Thursday, January 26, 2012, it will release its results for the second quarter and six months of fiscal year 2012, ended December 31, 2011. A press release with ResMed's results will be issued after 1:00 p.m. Pacific Time and the company will host a conference call and webcast to review its results, market trends, and future outlook. **Please note only the "outside US" number on the day of the conference call has been changed.**

(Logo: <https://photos.prnewswire.com/prnh/20100203/RESMEDLOGO>)

The conference call is scheduled to begin at 1:30 p.m. Pacific Time and will be webcast on ResMed's website at <http://investor.resmed.com>. Please go to this section of the website 5-10 minutes before the call and click on the icon for the "Q2 2012 results webcast". The online archive of the broadcast will be available approximately 30 minutes after the live call and will continue to be available for two weeks.

International conference call times will be:

9:30 p.m. London  
8:30 a.m. Sydney, Australia (January 27, 2012)

**TO PARTICIPATE** in the conference call, please call one of the numbers below at least 10 minutes before the call begins and identify yourself to the operator:

US: 617-614-3672  
**Outside US: +1 617-614-3672**  
Conference Name: Q2 2012 ResMed Inc. Results Conference Call  
Participant Passcode: 92354908

The replay of the conference call will be available approximately 30 minutes after the call and will be accessible for two weeks at:

US: 617-801-6888  
Outside US: +1 617-801-6888  
Passcode: 23854403

ResMed is a global leader in the development, manufacturing and marketing of medical products for the diagnosis, treatment and management of respiratory disorders, with a focus

on sleep-disordered breathing. The company is dedicated to developing innovative products to improve the lives of those who suffer from these conditions and to increasing awareness among patients and healthcare professionals of the potentially serious health consequences of untreated sleep-disordered breathing.

Further information can be obtained by contacting Constance Bienfait at ResMed Inc. at +1 (858) 836-5971, or by visiting the company's website at [www.resmed.com](http://www.resmed.com).

SOURCE ResMed Inc.